Association of homocysteine level with biopsy-proven non-alcoholic fatty liver disease: A meta-analysis

Journal of Clinical Biochemistry and Nutrition

Volumn 58, Issue 1, 2016, Pages 76-83

  Dai, Yining ^a   Zhu, Jinzhou ^a   Meng, Di ^a   Yu, Chaohui ^a   Li, Youming ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Folate; Homocysteine; Hyperhomocysteinemia; Non alcoholic fatty liver disease; Vitamin B12

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE;

AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD BIOCHEMISTRY; DISEASE ASSOCIATION; FOLIC ACID BLOOD LEVEL; HUMAN; HYPERHOMOCYSTEINEMIA; LIVER BIOPSY; NONALCOHOLIC FATTY LIVER; SYSTEMATIC REVIEW; VITAMIN BLOOD LEVEL;

EID: 84957708967     PISSN: 09120009     EISSN: None     Source Type: Journal    
DOI: 10.3164/jcbn.15-54     Document Type: Article

References (42)

1. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142: 1592-1609.
2. Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-140.
3. Méndez-Sánchez N, Arrese M, Zamora-Valdés D, Uribe M. Current concepts in the pathogenesis of nonalcoholic fatty liver disease. Liver Int 2007; 27: 423-433.
4. Selhub J. Homocysteine metabolism. Annu Rev Nutr 1999; 19: 217-246.
5. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-1057.
6. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002; 288: 2015-2022.
7. Ji Y, Tan S, Xu Y, et al. Vitamin B supplementation, homocysteine levels, and the risk of cerebrovascular disease: a meta-analysis. Neurology 2013; 81: 1298-1307.
8. Yang J, Hu X, Zhang Q, Cao H, Wang J, Liu B. Homocysteine level and risk of fracture: a meta-analysis and systematic review. Bone 2012; 51: 376-382.
9. Huang T, Ren J, Huang J, Liu D. Association of homocysteine with type 2 diabetes: a meta-analysis implementing Mendelian randomization approach. BMC Genomics 2013; 14: 867.
10. Jager A, Kostense PJ, Nijpels G, et al. Serum homocysteine levels are associated with the development of (micro)albuminuria: the Hoorn study. Arterioscler Thromb Vasc Biol 2001; 21: 74-81.
11. Mehedint MG, Zeisel SH. Choline's role in maintaining liver function: new evidence for epigenetic mechanisms. Curr Opin Clin Nutr Metab Care 2013; 16: 339-345.
12. Obeid R, Herrmann W. Homocysteine and lipids: S-adenosyl methionine as a key intermediate. FEBS Lett 2009; 583: 1215-1225.
13. Werstuck GH, Lentz SR, Dayal S, et al. Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J Clin Invest 2001; 107: 1263-1273.
14. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009; 62: e1-e34.
15. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 2007; 147: 573-577.
16. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
17. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558.
18. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
19. Thornton A, Lee P. Publication bias in meta-analysis: its causes and consequences. J Clin Epidemiol 2000; 53: 207-216.
20. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
21. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101.
22. de Carvalho SC, Muniz MT, Siqueira MD, et al. Plasmatic higher levels of homocysteine in non-alcoholic fatty liver disease (NAFLD). Nutr J 2013; 12: 37.
23. Franco Brochado MJ, Domenici FA, Candolo Martinelli Ade L, et al. Methylenetetrahydrofolate reductase gene polymorphism and serum homocysteine levels in nonalcoholic fatty liver disease. Ann Nutr Metab 2013; 63: 193-199.
24. Gulsen M, Yesilova Z, Bagci S, et al. Elevated plasma homocysteine concentrations as a predictor of steatohepatitis in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2005; 20: 1448-1455.
25. Hirsch S, Poniachick J, Avendaño M, et al. Serum folate and homocysteine levels in obese females with non-alcoholic fatty liver. Nutrition 2005; 21: 137-141.
26. Kalhan SC, Guo L, Edmison J, et al. Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism 2011; 60: 404-413.
27. Polyzos SA, Kountouras J, Patsiaoura K, et al. Serum homocysteine levels in patients with nonalcoholic fatty liver disease. Ann Hepatol 2012; 11: 68-76.
28. Leach NV, Dronca E, Vesa SC, et al. Serum homocysteine levels, oxidative stress and cardiovascular risk in non-alcoholic steatohepatitis. Eur J Intern Med 2014; 25: 762-767.
29. Sazci A, Akpinar G, Aygun C, Ergul E, Senturk O, Hulagu S. Association of apolipoprotein E polymorphisms in patients with non-alcoholic steatohepatitis. Dig Dis Sci 2008; 53: 3218-3224.
30. Bravo E, Palleschi S, Aspichueta P, et al. High fat diet-induced non alcoholic fatty liver disease in rats is associated with hyperhomocysteinemia caused by down regulation of the transsulphuration pathway. Lipids Health Dis 2011; 10: 60.
31. Meigs JB, Jacques PF, Selhub J, et al. Fasting plasma homocysteine levels in the insulin resistance syndrome: the Framingham offspring study. Diabetes Care 2001; 24: 1403-1410.
32. Nafiye Y, Sevtap K, Muammer D, Emre O, Senol K, Leyla M. The effect of serum and intrafollicular insulin resistance parameters and homocysteine levels of nonobese, nonhyperandrogenemic polycystic ovary syndrome patients on in vitro fertilization outcome. Fertil Steril 2010; 93: 1864-1869.
33. Fonseca VA, Mudaliar S, Schmidt B, Fink LM, Kern PA, Henry RR. Plasma homocysteine concentrations are regulated by acute hyperinsulinemia in nondiabetic but not type 2 diabetic subjects. Metabolism 1998; 47: 686-689.
34. Noga AA, Stead LM, Zhao Y, Brosnan ME, Brosnan JT, Vance DE. Plasma homocysteine is regulated by phospholipid methylation. J Biol Chem 2003; 278: 5952-5955.
35. Dara L, Ji C, Kaplowitz N. The contribution of endoplasmic reticulum stress to liver diseases. Hepatology 2011; 53: 1752-1763.
36. Aissa AF, Tryndyak V, de Conti A, et al. Effect of methionine-deficient and methionine-supplemented diets on the hepatic one-carbon and lipid metabolism in mice. Mol Nutr Food Res 2014; 58: 1502-1512.
37. Ji C. Dissection of endoplasmic reticulum stress signaling in alcoholic and non-alcoholic liver injury. J Gastroenterol Hepatol 2008; 23 (Suppl 1): S16-S24.
38. Wall RT, Harlan JM, Harker LA, Striker GE. Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb Res 1980; 18: 113-121.
39. Blann AD. Endothelial cell damage and homocysteine. Atherosclerosis 1992; 94: 89-91.
40. Yi X, Zhou Y, Jiang D, Li X, Guo Y, Jiang X. Efficacy of folic acid supplementation on endothelial function and plasma homocysteine concentration in coronary artery disease: a meta-analysis of randomized controlled trials. Exp Ther Med 2014; 7: 1100-1110.
41. Han JM, Jo AN, Lee SM, et al. Associations between intakes of individual nutrients or whole food groups and non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol 2014; 29: 1265-1272.
42. Charatcharoenwitthaya P, Levy C, Angulo P, Keach J, Jorgensen R, Lindor KD. Open-label pilot study of folic acid in patients with nonalcoholic steatohepatitis. Liver Int 2007; 27: 220-226.